Safety Evaluation of Contezolid (MRX-I) Versus Linezolid in Sprague-Dawley Rats
Abstract Background & Objectives Contezolid (MRX-I) is a novel ortho-fluorophenyl dihydropyridone developed by MicuRx Pharmaceuticals, Inc. It has been approved for the treatment of drug-resistant Gram-positive bacterial infections with relatively lower toxicity than other oxazolidinones such as lin...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Adis, Springer Healthcare
2025-05-01
|
| Cyfres: | Drugs in R&D |
| Mynediad Ar-lein: | https://doi.org/10.1007/s40268-025-00504-x |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|